These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35738464)

  • 1. Hydrogel-forming microarray patches with cyclodextrin drug reservoirs for long-acting delivery of poorly soluble cabotegravir sodium for HIV Pre-Exposure Prophylaxis.
    Volpe-Zanutto F; Vora LK; Tekko IA; McKenna PE; Permana AD; Sabri AH; Anjani QK; McCarthy HO; Paredes AJ; Donnelly RF
    J Control Release; 2022 Aug; 348():771-785. PubMed ID: 35738464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis.
    Pons-Faudoa FP; Sizovs A; Di Trani N; Paez-Mayorga J; Bruno G; Rhudy J; Manohar M; Gwenden K; Martini C; Chua CYX; Varchi G; Marzinke MA; Grattoni A
    J Control Release; 2019 Jul; 306():89-96. PubMed ID: 31136811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intradermal delivery of the antiretroviral drugs cabotegravir and rilpivirine by dissolving microarray patches: Investigation of lymphatic uptake.
    Ramöller IK; Volpe-Zanutto F; Vora LK; Abbate MTA; Hutton ARJ; McKenna PE; Peng K; Tekko IA; Sabri A; McAlister E; McCarthy HO; Paredes AJ; Donnelly RF
    J Control Release; 2024 Feb; 366():548-566. PubMed ID: 38211640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Evaluation of Dissolving Microarray Patches for Co-administered and Repeated Intradermal Delivery of Long-acting Rilpivirine and Cabotegravir Nanosuspensions for Paediatric HIV Antiretroviral Therapy.
    Moffatt K; Tekko IA; Vora L; Volpe-Zanutto F; Hutton ARJ; Mistilis J; Jarrahian C; Akhavein N; Weber AD; McCarthy HO; Donnelly RF
    Pharm Res; 2023 Jul; 40(7):1673-1696. PubMed ID: 36224503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bilayer Microarray Patch (MAP) for HIV Pre-Exposure Prophylaxis: The Role of MAP Designs and Formulation Composition in Enhancing Long-Acting Drug Delivery.
    Vora LK; Tekko IA; Zanutto FV; Sabri A; Choy RKM; Mistilis J; Kwarteng P; Jarrahian C; McCarthy HO; Donnelly RF
    Pharmaceutics; 2024 Jan; 16(1):. PubMed ID: 38276512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and characterisation of novel poly (vinyl alcohol)/poly (vinyl pyrrolidone)-based hydrogel-forming microneedle arrays for enhanced and sustained transdermal delivery of methotrexate.
    Tekko IA; Chen G; Domínguez-Robles J; Thakur RRS; Hamdan IMN; Vora L; Larrañeta E; McElnay JC; McCarthy HO; Rooney M; Donnelly RF
    Int J Pharm; 2020 Aug; 586():119580. PubMed ID: 32593650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrogel-forming microarray patches with solid dispersion reservoirs for transdermal long-acting microdepot delivery of a hydrophobic drug.
    Naser YA; Tekko IA; Vora LK; Peng K; Anjani QK; Greer B; Elliott C; McCarthy HO; Donnelly RF
    J Control Release; 2023 Apr; 356():416-433. PubMed ID: 36878320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development, Evaluation, and Pharmacokinetic Assessment of Polymeric Microarray Patches for Transdermal Delivery of Vancomycin Hydrochloride.
    Ramadon D; Permana AD; Courtenay AJ; McCrudden MTC; Tekko IA; McAlister E; Anjani QK; Utomo E; McCarthy HO; Donnelly RF
    Mol Pharm; 2020 Sep; 17(9):3353-3368. PubMed ID: 32706591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multitasking Pharmacophores Support Cabotegravir-Based Long-Acting HIV Pre-Exposure Prophylaxis (PrEP).
    Wan Z; Shi M; Gong Y; Lucci M; Li J; Zhou J; Yang XL; Lelli M; He X; Mao J
    Molecules; 2024 Jan; 29(2):. PubMed ID: 38257288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population pharmacokinetic model based on HPTN 077 of long-acting injectable cabotegravir for HIV PrEP.
    Yu Y; Bigos KL; Marzinke MA; Landovitz RJ; McCauley M; Ford S; Hendrix CW; Bies RR; Weld ED;
    Br J Clin Pharmacol; 2022 Oct; 88(10):4623-4632. PubMed ID: 35949044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Potential Impact of Long-Acting Cabotegravir for HIV Prevention in South Africa: A Mathematical Modeling Study.
    Smith JA; Garnett GP; Hallett TB
    J Infect Dis; 2021 Oct; 224(7):1179-1186. PubMed ID: 32492704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymeric Microarray Patches for Enhanced Transdermal Delivery of the Poorly Soluble Drug Olanzapine.
    McKenna PE; Abbate MTA; Vora LK; Sabri AH; Peng K; Volpe-Zanutto F; Tekko IA; Permana AD; Maguire C; Dineen D; Kearney MC; Larrañeta E; Paredes AJ; Donnelly RF
    ACS Appl Mater Interfaces; 2023 Jul; 15(26):31300-31319. PubMed ID: 37349320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans.
    Kinvig H; Rajoli RKR; Pertinez H; Vora LK; Volpe-Zanutto F; Donnelly RF; Rannard S; Flexner C; Siccardi M; Owen A
    Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38140050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1.
    McPherson TD; Sobieszczyk ME; Markowitz M
    Expert Opin Investig Drugs; 2018 Apr; 27(4):413-420. PubMed ID: 29633869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transgender Women's Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP).
    Rael CT; Lopez-Ríos J; McKenna SA; Das D; Dolezal C; Abascal E; Carballo-Diéguez A; Schnall R; Hope TJ; Bauermeister J; Bockting W
    AIDS Behav; 2021 Dec; 25(12):4180-4192. PubMed ID: 34216284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection.
    Radzio-Basu J; Council O; Cong ME; Ruone S; Newton A; Wei X; Mitchell J; Ellis S; Petropoulos CJ; Huang W; Spreen W; Heneine W; García-Lerma JG
    Nat Commun; 2019 May; 10(1):2005. PubMed ID: 31043606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection.
    Young IC; Massud I; Cottrell ML; Shrivastava R; Maturavongsadit P; Prasher A; Wong-Sam A; Dinh C; Edwards T; Mrotz V; Mitchell J; Seixas JN; Pallerla A; Thorson A; Schauer A; Sykes C; De la Cruz G; Montgomery SA; Kashuba ADM; Heneine W; Dobard CW; Kovarova M; Garcia JV; García-Lerma JG; Benhabbour SR
    Nat Commun; 2023 Feb; 14(1):708. PubMed ID: 36759645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving preparedness for introducing and scaling up long-acting HIV pre-exposure prophylaxis in Asia.
    Bavinton BR; Schmidt HA; Mills S; Phanuphak N
    Sex Health; 2024 Jun; 21():. PubMed ID: 38833542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension.
    Mc Crudden MTC; Larrañeta E; Clark A; Jarrahian C; Rein-Weston A; Lachau-Durand S; Niemeijer N; Williams P; Haeck C; McCarthy HO; Zehrung D; Donnelly RF
    J Control Release; 2018 Dec; 292():119-129. PubMed ID: 30395897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tip loaded cyclodextrin-carvedilol complexes microarray patches.
    Anjani QK; Sabri AHB; Hamid KA; Moreno-Castellanos N; Li H; Donnelly RF
    Carbohydr Polym; 2023 Nov; 320():121194. PubMed ID: 37659788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.